Table 1 Active clinical trials combining radiation with CTLA-4 inhibition
From: Current clinical trials testing the combination of immunotherapy with radiotherapy
NCT Number | Phase | Title | Conditions | Interventions | RT Details | Enrollment | Sponsor/Collaborators |
|---|---|---|---|---|---|---|---|
NCT01711515 | Phase 1 | Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer | Cervical Cancer | Cisplatin, Ipilimumab | EBRT 6Â weeks | 28 | National Cancer Institute (NCI) |
NCT02406183 | Phase 1 | Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma | Melanoma | Ipilimumab | SBRT 8-12 Gy × 3 fx | 21 | Radiotherapie|University Hospital, Ghent |
NCT01935921 | Phase 1 | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | Stage III-IVB Head and Neck Cancer | Cetuximab, Ipilimumab | IMRT, 7 wks | 18 | National Cancer Institute (NCI) |
NCT02659540 | Phase 1 | A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma | Melanoma | Ipilimumab, Nivolumab | EBRT 3 Gy × 10 fx or 9 Gy × 3 fx | 18 | Ludwig Institute for Cancer Research|Bristol-Myers Squibb |
NCT01860430 | Phase 1 | A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer | Head and Neck Cancer | Ipilimumab, Cetuximab | IMRT, 7 wks | 18 | University of Pittsburgh|National Cancer Institute (NCI) |
NCT01996202 | Phase 1 | A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma | Melanoma | Ipilimumab | EBRT | 24 | Duke University |
NCT02311361 | Phase 1 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | Pancreatic Cancer | Tremelimumab, MEDI4736 | SBRT, 1-5 fx | 60 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
NCT02239900 | Phase 1|Phase 2 | Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | Liver cancer, Lung Cancer | Ipilimumab | SBRT 12.5 Gy × 4 fx | 120 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
NCT02696993 | Phase 1|Phase 2 | Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer | Brain Metastases (NSCLC) | Nivolumab, Ipilimumab | WBRT 3 Gy × 10 fx, SRS 1 fxa | 80 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
NCT02254772 | Phase 1|Phase 2 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | B-cell Lymphoma | Ipilimumab, TLR9 agonist SD-101 | RT days 1, 2 | 27 | Ronald Levy|National Cancer Institute (NCI)|Stanford University |
NCT01565837 | Phase 2 | SART: Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma | Melanoma | Ipilimumab | SBRT 1-5 fx | 50 | Wolfram Samlowski|Comprehensive Cancer Centers of Nevada |
NCT01970527 | Phase 2 | Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | Recurrent/Stage IV Melanoma | Ipilimumab | SBRT 3 fx | 40 | Â |
NCT02107755 | Phase 2 | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | Melanoma | Ipilimumab | SBRT | 32 | Ohio State University Comprehensive Cancer Center|Bristol-Myers Squibb |
NCT02097732 | Phase 2 | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | Brain Metastases (Melanoma) | Ipilimumab | SRS 1 fxa | 40 | University of Michigan Cancer Center |
NCT02115139 | Phase 2 | GRAY-B: GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases | Melanoma | Ipilimumab | WBRT 3 Gy × 10 fx | 66 | Grupo Espanol Multidisciplinar de Melanoma|Bristol-Myers Squibb |
NCT02701400 | Phase 2 | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Tremelimumab, Durvalumab | SBRT | 20 | Emory University|AstraZeneca |
NCT02434081 | Phase 2 | NICOLAS: NIvolumab COnsolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC | NSCLC | Nivolumab | EBRT | 43 | European Thoracic Oncology Platform|Bristol-Myers Squibb|Frontier Science Foundation, Hellas |
NCT01449279 | Pilot | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | Stage IV Melanoma | Ipilimumab | Palliative RT | 20 | Stanford University |